Abstract
Breast cancer has become the leading cancer among Indian women, accounting for more than one in four female malignancies. Despite being one of the most treatable cancers if detected early, nearly 60% of Indian cases are still diagnosed at advanced stages, and survival rates remain well below global averages. Thus, breast cancer becomes not merely a biomedical condition but a systemic challenge that mirrors broader gaps in equity, financing, and governance within India’s health architecture. Drawing on the World Health Organization’s six health system building blocks, we analyse how breast cancer mirrors both the strengths and weaknesses of India’s broader health system.
Service delivery has expanded through the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), integrating cancer screening within primary healthcare, and through tertiary infrastructure under the Strengthening of Tertiary Care for Cancer Scheme. State Cancer Institutes, Tertiary Cancer Centres, and Ayushman Arogya Mandirs (formerly Health and Wellness Centres) have broadened the service base. Yet, screening remains largely opportunistic with only about 1% of women aged 30–49 having ever undergone a breast examination, and diagnostic capacity concentrated in urban hubs. Decentralized state models such as Kerala’s ASWAS initiative and Tamil Nadu’s district cancer centres demonstrate that community-led and locally financed delivery can dramatically improve early detection and continuity of care.
Further, the health workforce remains constrained by shortages of oncologists, oncology nurses, and pathologists, especially in rural areas. India has roughly one medical oncologist per million people, and oncology training opportunities remain limited. However, tele-mentoring initiatives like Project ECHO and community-based awareness programmes led by ASHAs and ANMs are gradually extending the reach of early detection and patient navigation. Sustained investment in skill development, multidisciplinary training, and supportive supervision can transform the workforce from specialist-driven to system-enabled.
Furthermore, health information systems have strengthened with the expansion of the National Cancer Registry Programme (NCRP), now covering around 18% of the population. These registries provide vital data on regional patterns and survival outcomes, yet coverage remains uneven, particularly in rural and northeastern regions. Integration of NCRP with digital platforms under the Ayushman Bharat Digital Mission (ABDM) offers an opportunity for longitudinal patient tracking, improved referral linkages, and real-time monitoring of outcomes. Institutionalizing cancer indicators within national surveys like NFHS and DLHS can further enhance accountability and policy responsiveness.
In access to medicines and technologies, India has made notable progress through the availability of generic chemotherapy drugs and regulatory reforms such as the National Pharmaceutical Pricing Authority’s (NPPA) trade margin caps on anti-cancer medicines, which have reduced prices significantly. Tamil Nadu’s pooled procurement model has proven effective in ensuring timely and affordable drug availability. However, access to costly biologics such as trastuzumab remains limited, and radiotherapy infrastructure falls short of WHO benchmarks, with only one-fourth of patients able to access radiation. Expanding pooled procurement, exploring differential pricing arrangements for innovative molecules, incentivizing biosimilars, and leveraging public–private partnerships for radiotherapy capacity are critical next steps.
Additionally, financing also remains a major determinant of inequity. Despite Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) and various state insurance schemes providing partial financial protection, out-of-pocket expenditure for cancer still accounts for 60–80% of total spending, with catastrophic costs affecting most households. Broader coverage of diagnostics, follow-up, and non-medical expenses, along with value-based purchasing and innovative financing mechanisms such as social impact bonds, can enhance both efficiency and equity.
Finally, leadership and governance have evolved with strong national frameworks like NP-NCD and the National Programme for Palliative Care, complemented by state-led innovations. Kerala and Tamil Nadu exemplify effective decentralized governance through locally funded screening drives and integrated care pathways. Yet, coordination between central and state agencies, weak monitoring, and fragmented accountability continue to impede outcomes. Strengthening institutional stewardship, defining clear roles across governance levels, and embedding quality audits can ensure policy coherence and sustained implementation.
Overall, India’s breast cancer response reflects both maturity and fragmentation. The country possesses all the foundational blocks needed to transform outcomes. But if India is to “bend the curve” of its breast cancer epidemic, it needs to move beyond programmatic silos toward a truly integrated system that connects prevention, detection, diagnosis, treatment, and survivorship: from prevention to palliation (P2P). Because ultimately, how we respond will define not just survival rates, but also the empathy, resilience, responsiveness, and fairness of India’s health system.
Introduction
Breast cancer has quietly but decisively become India’s leading cancer among women, overtaking cervical cancer, a shift that signals changing epidemiological patterns and a growing public health burden. In 2022, India recorded nearly 192,000 new breast cancer cases, accounting for over one-quarter of all female cancers, and the numbers continue to rise. By 2024, an estimated 238,000 women will be newly diagnosed, making breast cancer the most common malignancy among Indian women., Data from the National Cancer Registry Programme reveal that breast cancer represented about 13.5% of all new cancers and 10% of cancer deaths among women in 2020.2 The disease’s geography tells its own story: incidence rates in urban hubs like Hyderabad (≈54 per 100,000) are tenfold higher than in remote regions such as Dima Hasao, Assam (<5 per 100,000).3 These disparities reflect not biology, but structural inequities in awareness, screening, and access to timely care. Even where treatment is available, survival outcomes are sobering. India’s five-year relative survival rate for breast cancer is only about 66%, well below global averages, and plummets to as low as 42% in underserved regions. The data also reveal an underlying crisis: nearly 57% of Indian breast cancers are diagnosed at stage II or III, long after the window for early, curative intervention has closed, resulting in high mortality despite the disease’s treatability.4
Consequently, breast cancer in India is no longer merely a medical condition; it has become a mirror reflecting systemic inequities in prevention, early detection, access, and outcomes. From fragmented screening programs to the uneven distribution of oncology infrastructure, the contours of breast cancer mirror broader challenges in health system equity, financing, and regional capacity. Unless India reimagines how it detects, finances, and delivers cancer care, particularly for women, it risks not only a continued rise in incidence but a deepening injustice in survival. Therefore, an integrated, equitable, and effective approach spanning the full continuum of care, from prevention to palliation (P2P), is now an urgent national imperative. The World Health Organization’s six health system “building blocks”: service delivery, health workforce, health information systems, access to essential medicines and technologies, financing, and governance, provide a useful analytical lens to evaluate how well the country’s institutions, policies, and delivery mechanisms are positioned to confront the breast cancer challenge. Applying this framework allows for a structured assessment of both systemic strengths and persistent vulnerabilities across the full continuum of care.
- Service Delivery: Expanding Care Across the Continuum
Prevention and Screening
Effective service delivery for breast cancer begins in the community, where awareness, education, and early detection hold the greatest potential to save lives. With the launch of the National Programme for Control of Cancer, Diabetes, CVD and Stroke in 2010, now renamed as the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), the cancer control efforts in India have been integrated into an umbrella framework addressing a broad spectrum of non-communicable diseases (NCDs) under the National Health Mission (NHM).12 The NP-NCD operates to reduce mortality and morbidity from cancer and other NCDs through preventive, promotive, curative, and rehabilitative services. The program encompasses several critical activities aimed at enhancing cancer care and prevention. An important component of the program emphasizes community-based screening initiatives, focusing on early detection of common cancers, including breast cancer, leveraging grassroots health workers to reach a broader population. Despite this foundation, screening coverage remains limited, suggesting the need for deeper system integration rather than programmatic redesign. The NFHS-5 (2019–21) survey reported that only 0.9% of women aged 30–49 years had ever undergone a breast examination. Most states recorded screening coverage below 2%, with Tamil Nadu (~5.6%) and Kerala (2–3%) emerging as notable front-runners.5, While these figures remain modest compared with global benchmarks, they point to states where policy intent, training, and local innovation have begun to translate into measurable progress.
The primary challenge lies not in intent but in implementation architecture. Screening in India continues to be largely “opportunistic,” often conducted through health camps or outpatient visits, rather than as part of systematic population-level outreach. This model depends heavily on frontline health workers, ASHA, and ANM staff, whose capacity and training for clinical breast examination (CBE) vary widely. Encouragingly, localized innovations demonstrate what is possible when systems are strengthened. A study from rural Tamil Nadu found that even where awareness levels exceeded 50%, only around 16% of women had been screened. In contrast, Kerala’s “ASWAS” initiative, a door-to-door screening campaign in Kannur, achieved an impressive 93% coverage among one million women, by mobilizing trained volunteers and leveraging local governance and funding structures. Such examples underscore that community-led, decentralized models can transform early detection. Emerging digital health tools and artificial intelligence (AI) are also opening new frontiers for bridging access gaps in prevention and screening, particularly in underserved and rural regions. AI-based thermal imaging, automated visual inspection, and low-cost portable mammography solutions have shown promise in detecting abnormalities even in primary care settings with limited radiology infrastructure. These pilots could be further consolidated and scaled under India’s National Mission on Artificial Intelligence to enable remote diagnostics, teleconsultation, and real-time reporting through digital health records in resource-constrained settings.
Scaling up these successes would require systematic training of frontline workers in CBE, the deployment of mobile screening units, and the integration of screening services more robustly within Ayushman Bharat Health and Wellness Centres (AB-HWCs), now Ayushman Arogya Mandirs (AAMs), which aim to offer comprehensive non-communicable disease (NCD) screening. With proper investment in capacity-building, India can move from fragmented to population-based screening, ensuring that early detection becomes an accessible and routine part of primary care.
Diagnosis and Treatment
Once a lump is found, the next step is timely diagnosis and curative treatment. Here too, India’s health system shows both remarkable strengths and persistent spatial inequities. Under the Strengthening of Tertiary Care for Cancer Scheme, significant progress has been made through the establishment of State Cancer Institutes (SCIs) and Tertiary Care Cancer Centres (TCCCs), along with apex institutions such as the National Cancer Institutes. These initiatives have expanded the country’s tertiary cancer care infrastructure, creating centres of excellence for advanced diagnostics, chemotherapy, radiotherapy, and surgical oncology.
However, these services remain concentrated in metropolitan centres and select states, while many district hospitals lack the infrastructure for pathology, imaging, or biopsy, forcing patients, particularly from rural and remote regions, to travel long distances to tertiary centres for confirmatory diagnosis. Registry data and surveys show that rural patients present with larger tumors and more metastasis at diagnosis than urban patients (reflecting delayed detection). Their survival rates are also lower than urban centres.4 Where services do exist, quality varies. For instance, many public hospitals continue to rely on mastectomy as the default surgery, rather than breast-conserving procedures, due to resource limitations. Overall, the public health delivery system has limited capacity for complex care, and private care is expensive. These delivery gaps are often reflected in health outcomes. The recent NCRP analysis found that over half of breast cancer patients are diagnosed at stage II or III. Late-stage diagnosis means more advanced surgery, chemotherapy, and lower cure rates. Even when treated, continuity of care is uneven: follow-up surveillance and survivorship clinics are rare, especially in public facilities.
Nevertheless, several states are demonstrating promising models of decentralized cancer care. Tamil Nadu’s establishment of district cancer centres and subsidized diagnostic services has begun to shorten referral pathways and improve timely access. Similarly, Kerala has integrated panchayat-led cancer control initiatives with public hospitals, supported by local funding and trained volunteers, offering a model of community-enabled care that other states can adapt. These innovations point the way toward a more integrated continuum of care, where detection, diagnosis, and treatment are seamlessly connected across primary, secondary, and tertiary levels. Strengthening this continuum would reduce diagnostic delays, improve treatment outcomes, and ensure that care is not determined by geography or income.
Survivorship and Palliative Care
While extending curative care is vital, support for women after treatment (survivorship) and for those with incurable disease (palliative care) is often neglected in policy but is part of the continuum. Survivorship in India is a largely informal concept: few hospitals have dedicated follow-up clinics or psychosocial support services for breast cancer survivors. Palliative care is even more under-resourced. According to a recent study, ~98% of Indian patients with metastatic (stage IV) cancer receive no palliative care. In women with breast cancer, this translates to over 20,000 patients in 2020 who endured advanced disease without relief.11 We have in place the National Programme for Palliative Care, though well-intentioned, but it has remained limited in its scope and coverage, and achieved meaningful success only in a few states like Kerala, where a community-based, decentralized model has set the national standard. In most other states, programmatic reach remains minimal. Therefore, it becomes imperative to integrate palliative care training into medical and nursing curricula. State and district health plans should designate palliative services (e.g. at community health centres) and ensure home-based care teams. International experience shows that expanding palliative care significantly improves quality of life with relatively low investment, which India sorely needs as cancer prevalence rises.
- Health Workforce: Building Capacity at All Levels
India’s health workforce is at the heart of its response to the rising breast cancer burden. However, specialist density remains lower than desired, with roughly one medical oncologist per million people. Likewise, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and counselors remain short in supply, especially in rural districts. Most cancer specialists are clustered in big cities and academic hospitals. However, across many states, frontline workers are increasingly driving early detection and awareness efforts at the grassroots level. The opportunity now lies in building on this momentum, and strengthening the skill mix across all levels of care, from primary to tertiary, can ensure that every woman has access to timely diagnosis and treatment. Training frontline providers in cancer awareness, breast examination, and referral pathways has already shown encouraging results in pilot programs, demonstrating that community-based screening can be both cost-effective and scalable. The success of ASHA and ANM-led initiatives underscores the value of empowering existing human resources rather than relying solely on specialists.
India’s robust medical education system also provides a strong platform for workforce expansion. Increasing oncology MD/DNB and fellowship positions represents a feasible next step. Several states and academic centres have already begun introducing oncology training modules, and national tele-mentoring platforms, such as Project ECHO, are helping extend expertise to rural and district hospitals. Such blended learning and mentorship models can accelerate skill transfer and improve confidence among general practitioners in managing early cancers. Further, community engagement remains a powerful complement to professional training. Kerala’s ASWAS initiative, which successfully trained over 8,000 women volunteers to support early detection efforts, illustrates how locally embedded, community-driven approaches can extend the reach of formal health services. Scaling similar models across states, supported by structured supervision, career incentives, and modest remuneration, can help bridge workforce gaps while deepening community trust and participation. With sustained investment, skill development, and policy support, India’s health workforce can evolve into a more balanced, multidisciplinary system, one that not only detects and treats breast cancer early but also supports survivors and their families across the continuum of care.
- Health Information Systems: Data for Action
Timely and accurate data form the backbone of an effective cancer control strategy. In India, the National Cancer Registry Programme (NCRP) has played a pivotal role in generating robust evidence on cancer incidence and patterns. Its expanding network, comprising 43 population-based and 58 hospital-based registries, currently covers around 18% of the population.3 The Population-based registries take the sample population in a geographically defined area while the Hospital-based registries take the data from patients coming to a particular health institution. These registries have illuminated important regional trends, such as higher breast cancer incidence in southern India and among urban populations, thereby shaping more targeted policy responses. However, the coverage remains uneven, particularly in rural and north-eastern regions. Yet, the NCRP provides a strong foundation on which to build. Expanding population-based cancer registries (PBCRs) to underserved states and linking them with mortality and staging data would enable more comprehensive survival analyses and facilitate evaluation of program effectiveness. Strengthening data quality, timeliness, and interoperability across registries would also enhance India’s ability to plan resources and monitor outcomes in real time.
In addition to cancer registries, India has begun to collect population-level screening data. NFHS-5 (2019–21) is the first national survey to report breast cancer screening coverage, providing valuable baseline data. 5, Institutionalizing such indicators within the NFHS and District-Level Household Surveys will ensure consistent monitoring of awareness, screening, and health-seeking behaviours over time. Digital health initiatives under Ayushman Bharat Digital Mission (ABDM) further offer an unprecedented opportunity to strengthen cancer information systems. A unified electronic health record and patient-tracking platform, integrating data from screening, diagnosis, and treatment facilities, would help ensure continuity of care, reduce loss to follow-up, and enable longitudinal monitoring of survivors. Leveraging the ABDM for this purpose could greatly improve coordination across facilities and levels of care. Finally, expanding investment in operational research and state-level data analysis will be critical as context-specific evidence is essential to designing “multidisciplinary, locally relevant” interventions. Building a culture of data-driven decision-making, through research collaborations, open data platforms, and analytic capacity within health departments, will help India translate information into more effective, equitable breast cancer policies.
- Access to Essential Medicines and Technologies
Access to quality-assured and affordable medicines remains a cornerstone of equitable breast cancer care. For breast cancer, the therapeutic armamentarium spans cytotoxic chemotherapies (e.g., anthracyclines, taxanes), anti-hormonal agents (such as tamoxifen and aromatase inhibitors), and targeted biologics (including trastuzumab and pertuzumab). While generic formulations of older chemotherapy agents and tamoxifen are widely available in India, systemic barriers in procurement and distribution continue to constrain their reach, particularly in public facilities. Periodic stock-outs, fragmented state procurement systems, and delays in tendering often force patients to purchase drugs out-of-pocket, undermining financial protection goals. Bridging this gap requires a strategic shift from fragmented procurement to pooled and value-based purchasing models. Centralized or pooled procurement, such as through the Medical Services Corporation models pioneered by Tamil Nadu, has demonstrated substantial efficiency gains, enabling bulk negotiation, better price discovery, and timely distribution. Expanding such mechanisms across states under a common procurement framework could ensure consistent supply and reduce inter-state price variability. Furthermore, volume-based contracting and framework agreements with manufacturers can stabilize supply chains for high-demand oncology drugs, reducing per-unit cost while incentivizing quality compliance.
For high-cost biologics and targeted therapies, such as trastuzumab, which remains prohibitively expensive for most patients, differential pricing (tiered financing) arrangements can be transformative, ensuring access without crowding out private investments. The government could negotiate tiered pricing with manufacturers based on income or facility type, while selectively subsidizing treatment under national schemes such as the Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). Public financing instruments also hold the potential to shape markets and drive affordability. Mechanisms such as outcome-based contracts, where payments are linked to therapeutic effectiveness, and advance market commitments can incentivize competition among biosimilar manufacturers while ensuring cost sustainability. Additionally, the inclusion of all WHO and ICMR-recommended breast cancer therapies in the National List of Essential Medicines (NLEM) and Essential Diagnostics List (EDL), followed by coordinated state-level procurement, would institutionalize access and stabilize prices through pooled purchasing power. A strong precedent for the impact of regulatory intervention can also be seen in the National Pharmaceutical Pricing Authority (NPPA) initiative under the ‘Trade Margin Rationalization’ approach. On February 27, 2019, NPPA capped the trade margin at 30% for 42 selected non-scheduled anti-cancer medicines, resulting in significant price reductions. The number of medicines priced above ₹20,000 fell from 124 to 62 post-regulation, generating an estimated annual patient saving of ₹984 crore.
Beyond medicines, access to radiotherapy remains a critical bottleneck. Only about one-fourth of Indian cancer patients who require radiation can currently access it, well below WHO’s benchmark of one megavoltage machine per million population. This deficit not only delays curative treatment but also increases recurrence and mortality risks. A phased investment roadmap, prioritizing underserved states, is needed to bridge this gap. Leveraging public–private partnerships, through co-location, equipment leasing, or viability-gap funding could rapidly expand radiotherapy capacity without overburdening public budgets. Integrating radiotherapy units into regional cancer care hubs, linked via tele-oncology, would further enhance utilization and geographic equity.
Finally, pain relief and palliative medicines remain a neglected yet essential component of access. Oral morphine and other opioids, classified as essential by the WHO, remain under-prescribed due to regulatory barriers and restrictive licensing. Less than 1% of patients receive adequate pain management.10 Simplifying narcotic prescribing rules, decentralizing opioid supply to district hospitals, and integrating palliative medicine into essential drug procurement lists would ensure that “access” extends not just to curative care, but also to comfort and dignity. Taken together, aligning India’s pharmaceutical and technology procurement with principles of strategic purchasing, pooled negotiation, and evidence-based prioritization can significantly improve affordability and availability. Such reforms, embedded within the broader vision of Universal Health Coverage and Ayushman Bharat, would make breast cancer care both equitable and sustainable.
- Financing
Health financing remains a pivotal determinant of access to timely and comprehensive breast cancer care in India. While Government Health Expenditure (GHE) currently stands at around 1.8% of GDP, there is significant scope for expansion to align with India’s aspirations and global benchmarks for achieving Universal Health Coverage (UHC)., Out-of-pocket spending still accounts for an estimated 60–80% of total health expenditure in cancer care, among the highest globally.11 Cancer care, given its long treatment cycles and multi-modality nature, often becomes financially challenging even for middle-income families. Evidence suggests that a substantial proportion of women with breast cancer, up to 84%, experience catastrophic health expenditure (defined as health spending exceeding 20% of annual household income), and about 72% resort to distress financing through borrowing or asset sales.11 Such findings underline the economic vulnerability associated with breast cancer but also point toward the significant potential of system-level reforms to mitigate these burdens through more effective financial risk protection.
The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), along with various state-specific health insurance schemes, represents a major step toward improving financial protection for cancer patients. These schemes already cover a range of procedures, including cancer surgery, chemotherapy, and diagnostics, in empanelled hospitals. Yet, there is scope to strengthen both depth and breadth of coverage. Expanding empanelment of cancer centres, particularly in underserved regions; reducing preauthorization delays; and including non-medical expenses such as transport and accommodation support could substantially improve treatment continuity and equity. Enhancing awareness and financial literacy among beneficiaries would further ensure that the benefits reach women most in need. Financial assistance for cancer treatment is also provided to patients living below the poverty line, allowing them to receive medical treatment at government hospitals through the Health Minister’s Cancer Patient Fund (HMCPF) and Health Minister’s Discretionary Grants (HMDG) under Rashtriya Arogya Nidhi (RAN). Various state governments have also established State Illness Assistance Funds in parallel to funds under RAN to provide financial aid to impoverished patients, covering treatment expenses for various illnesses. However, utilization remains low.
Looking forward, India’s approach to financing cancer care could benefit from a more strategic and value-oriented framework. Key policy opportunities include strategic purchasing that links provider payments to outcomes and quality of care and innovative financing mechanisms, such as public–private partnerships or social impact bonds to fund prevention, early detection, and treatment for vulnerable groups. Strengthening public investment in cancer care infrastructure and ensuring dedicated budget lines for NCDs under the National Health Mission will also enhance financial sustainability. India’s challenge is not only to mobilize more resources for breast cancer care, but to deploy them more effectively.
- Leadership and Governance
Strong leadership and coherent policy direction form the backbone of any effective health system response. In India, recent years have seen notable progress toward a more structured approach to cancer control. The National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) under the National Health Mission provides a policy framework for prevention, screening, and management of cancers. The National Programme for Palliative Care (NPPC), launched in 2012, represents an important milestone in acknowledging end-of-life care as a public health priority. State governments, too, have demonstrated leadership through localized innovations, Tamil Nadu’s State Cancer Control Plan and Kerala’s decentralized cancer financing model are examples of proactive, context-specific approaches. At the global level, India’s commitments align with the WHO Global Breast Cancer Initiative (2021), which emphasizes early detection, timely diagnosis, and comprehensive treatment as pathways to improve survival outcomes. Despite these policy strides, implementation and accountability mechanisms remain areas of concern. Although population-based screening guidelines exist, India’s national screening programme has yet to yield the desired outcomes.5
Addressing these gaps calls for stronger institutional stewardship and a clear delineation of roles across governance levels. Setting annual district-level targets for breast cancer screening, ensuring routine quality audits of cancer care facilities, and integrating cancer-related interventions within broader initiatives such as Ayushman Bharat and Swachh Bharat can create coherence across programmes addressing social and environmental determinants of cancer. Kerala’s experience illustrates how governance innovations can drive results: district health authorities and local self-governments jointly funded the ASWAS screening drive, enhancing community reach and participation. Tamil Nadu, similarly, has institutionalized training for primary care providers in early cancer detection and rolled out statewide awareness campaigns, strengthening early diagnosis at scale. These experiences highlight that effective subnational leadership, backed by adequate financing and accountability systems, is critical for translating national policy intent into outcomes.
Given India’s federal health governance structure, a dual strategy is essential, central agencies such as ICMR and NCDIR should provide technical guidance, standardized data systems, and monitoring frameworks, while state governments retain the flexibility to adapt strategies to local contexts. Encouraging community participation through Panchayati Raj Institutions, self-help groups, and NGOs can further enhance ownership and sustainability of breast cancer initiatives. Ultimately, strengthening governance for breast cancer control is about creating clarity in roles, continuity in leadership, and coherence in action, ensuring that policy ambition is matched by accountability and local engagement.
Conclusion
Breast cancer in India represents a multifaceted public health challenge that necessitates a comprehensive health systems response. Evidence underscores that improvements in prevention and early detection can yield substantial reductions in mortality and morbidity; however, these gains are contingent upon the cohesive functioning of all six health system building blocks. Fragmented or vertical approaches have limited impact unless embedded within broader health system strengthening efforts. A systems-oriented strategy, therefore, is imperative, one that integrates early detection and screening within primary healthcare, strengthens referral linkages to secondary and tertiary care, ensures reliable supply chains for oncology drugs and diagnostics, and embeds performance monitoring within digital health platforms. Strategic purchasing, pooled procurement, and differential pricing mechanisms could further improve affordability and equitable access to essential therapies. Similarly, enhanced coordination between national and state agencies, coupled with decentralized implementation, can improve accountability and responsiveness to local needs.
Aligning resources and policies around these principles would enable India to “bend the curve” of its growing breast cancer burden. Early and sustained investments in prevention, screening, and early-stage treatment, consistent with WHO’s Global Breast Cancer Initiative, are likely to generate the highest health and economic returns. Achieving this, however, requires sustained political commitment, clear targets, and collaborative governance involving the public sector, private providers, non-governmental organizations, and communities. Ultimately, strengthening India’s breast cancer response is not merely a sectoral reform, it is an essential pathway toward realizing the country’s broader noncommunicable disease control agenda and Sustainable Development Goals. A resilient, equitable, and coordinated cancer care system will not only save lives but also reaffirm the state’s commitment to women’s health as a cornerstone of social and economic development.